Papillomavirus Infections Clinical Trial
Official title:
High-Risk HPV Infections in Women Aged 25 to 65
Verified date | November 2013 |
Source | University of Washington |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
The purpose of this study is to determine risk factors for HPV infections in 25 to 65 year old women who report having used internet dating websites in the past year.
Status | Completed |
Enrollment | 303 |
Est. completion date | December 2008 |
Est. primary completion date | December 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 25 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Have had sex with men - Have used the internet to search for romantic partners in the past year (e.g. posted or responded to an ad on an internet dating website or social networking website) Exclusion Criteria: - Pregnant, breastfeeding, or planning a pregnancy in the next 6 months - Hysterectomy |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | University of Washington | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
University of Washington | National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | High-Risk HPV DNA | four months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00973856 -
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
|
N/A | |
Active, not recruiting |
NCT05580341 -
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
|
Phase 3 | |
Completed |
NCT06399341 -
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
|
||
Recruiting |
NCT03548740 -
Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
|
||
Completed |
NCT00092547 -
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
|
Phase 3 | |
Completed |
NCT00157950 -
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
|
Phase 3 | |
Recruiting |
NCT00365729 -
Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men
|
N/A | |
Completed |
NCT03584308 -
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
|
Phase 2 | |
Not yet recruiting |
NCT04115787 -
Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
|
||
Completed |
NCT04072913 -
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
|
N/A | |
Completed |
NCT00549250 -
Human Papillomavirus 6/11 in the Lower Airway of Neonates
|
N/A | |
Recruiting |
NCT04694495 -
HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
|
||
Completed |
NCT06439433 -
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
|
Phase 2 | |
Completed |
NCT00380367 -
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
|
Phase 3 | |
Completed |
NCT01894425 -
Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation
|
N/A | |
Completed |
NCT00685412 -
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
|
Phase 1 | |
Completed |
NCT00365716 -
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
|
Phase 2 | |
Completed |
NCT04772534 -
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
|
Phase 3 | |
Completed |
NCT05119855 -
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
|
Phase 3 | |
Completed |
NCT03487549 -
Cantharidin and Occlusion in Verruca Epithelium
|
Phase 2 |